Xencor Inc
XNCR evidence brief
What we can confirm
- BioSniper Score:
- 7.7 / 10
- Market Cap:
- $1.88B
- Lead Asset:
- AIMab7195 (XmAb7195) (Phase 1)
What it means
What to watch
Prepared research question
What matters most for XNCR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XNCR
Xencor Inc is a clinical-stage biopharmaceutical company developing engineered bispecific antibodies for oncology and autoimmune diseases, with a focus on T-cell engagers and anti-inflammatory programs.
Key risk: Operating losses
BioSniper Score
Based on 4 of 6 signals
Market Cap
$1.88B
Cash Runway
—
Lead Asset
AIMab7195 (XmAb7195) (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 9 pipeline candidates · 12 clinical trials for Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company developing engineered bispecific antibodies for oncology and autoimmune diseases, with a focus on T-cell engagers and anti-inflammatory programs.
- Cash & equivalents of $44.7M as of 2026-06-30 [sec].
- Total revenue of $51.2M and net loss of -$21.7M as of 2026-06-30 [sec].
- Shareholders' equity of $503.2M and total debt of $104.9M as of 2026-06-30 [sec].
- Enrolling seven clinical studies across wholly owned XmAb drug candidates as of 2026-08-05 [sec_mda].
- Initiated global Phase 2b XENITH-UC study for XmAb942 in ulcerative colitis and plan to present additional clinical data in second half of 2026 [sec · filed 2026-04-27].
What works
- Strong cash position of $44.7M as of 2026-06-30 provides runway for ongoing clinical programs [sec].
- Multiple wholly owned clinical-stage programs in oncology (e.g., XmAb819) and autoimmune diseases (e.g., XmAb942) diversify pipeline risk [sec_mda · as of 2026-08-05].
- XmAb942 demonstrated favorable tolerability and extended half-life supporting 12-week maintenance dosing in first-in-human data [sec · filed 2026-04-27].
- Company has advanced a lead candidate for anti-TL1A x IL23p19 program and expanded preclinical pipeline in immunology and oncology [sec · filed 2026-04-27].
What to weigh
- Net loss of -$21.7M as of 2026-06-30 indicates ongoing operating losses [sec].
- Total debt of $104.9M as of 2026-06-30 represents a significant liability [sec].
- All programs are still in clinical stages with no approved products, meaning no commercial revenue from drug sales [sec_mda · as of 2026-08-05].
- Enrollment continues for key programs and pivotal studies are planned for 2027, so near-term catalysts are uncertain [sec · filed 2026-04-27].
From the filings
Quoted directly from source documents.
Enrolling seven clinical studies
“We are currently enrolling seven clinical studies to evaluate our XmAb drug candidates”
SEC MD&A · August 5, 2026
XmAb942 tolerability and dosing interval
“demonstrating favorable tolerability and an extended half-life supporting a 12-week maintenance dosing interval”
SEC filings · April 27, 2026
Risks & what to watch (4)›
Key risks
- Operating losses — Net loss of -$21.7M as of 2026-06-30 indicates ongoing cash burn [sec].
- Debt burden — Total debt of $104.9M as of 2026-06-30 may strain future finances [sec].
- No approved products — All programs are clinical-stage with no commercial revenue from drug sales [sec_mda].
- Clinical trial uncertainty — Pivotal studies planned for 2027; near-term catalysts depend on ongoing enrollment and data [sec].
What to watch
- Presentation of additional clinical data for XmAb942 and XmAb819 in second half of 2026 [sec · filed 2026-04-27].
- Initiation of first-in-human studies for XmAb412 in second half of 2026 [sec · filed 2026-04-27].
- Advancement toward pivotal studies planned for 2027 [sec · filed 2026-04-27].
- Cash runway and burn rate given $44.7M cash as of 2026-06-30 [sec].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Xencor Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Xencor Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.44 · 0% dilution
Lead: Approved
9 candidates
No upcoming catalysts tracked
0 buys · 5 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 19, 2026- % of float
- 21.7%
- Days to cover
- 11.4
- Shares short
- 11,295,359
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XNCR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Xencor Inc?
Xencor Inc is a clinical-stage biopharmaceutical company developing engineered bispecific antibodies for oncology and autoimmune diseases, with a focus on T-cell engagers and anti-inflammatory programs.
What is Xencor Inc's lead drug candidate?
Xencor Inc's most advanced tracked candidate is AIMab7195 (XmAb7195) (Phase 1) for allergic indications (designed to reduce blood levels of IgE).
Who is the CEO of Xencor Inc?
Dr. Bassil I. Dahiyat Ph.D. is the chief executive officer of Xencor Inc (XNCR).
Where is Xencor Inc headquartered?
Xencor Inc (XNCR) is headquartered in Pasadena, CA, United States.
What therapeutic areas does Xencor Inc focus on?
Xencor Inc develops therapies across Oncology, Immunology, Infectious Disease, Hematology, Nephrology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.